{"title":"Precision cell therapy: optimizing neural stem/progenitor cell regional identity for enhanced spinal cord repair and regeneration.","authors":"Aysu Kollu, Mohammad Khazaei, Michael G Fehlings","doi":"10.1093/stcltm/szag088","DOIUrl":"10.1093/stcltm/szag088","url":null,"abstract":"<p><p>Spinal cord injury (SCI) leads to severe sensorimotor and autonomic impairment, loss of independence, and increased mortality. Despite significant advances in surgical interventions, medical management, and rehabilitative approaches, there are currently no curative or regenerative therapies for SCI. Neural stem/progenitor cell (NSPC) transplantation is recognized as a promising strategy to achieve regeneration of the injured spinal cord due to their ability to replace the neuroglial populations that are lost and to restore the connectivity of neural circuits. The developmental regional identity of NSPCs has emerged as a key characteristic that influences the outcome of preclinical transplantation studies and how well the grafted cells can integrate into host circuitry. In the present review, we focus on NSPC regional identity, and how this fundamental developmental trait can impact the cells' ability to integrate into the injured spinal cord to promote functional recovery. We begin by introducing the developmental basis of spinal cord patterning, describing regional specification along the antero-posterior and dorso-ventral axes. We highlight studies that reveal the importance of NSPC regional identity for spinal cord regeneration. Finally, we discuss the distinct molecular characteristics that define spinal cord NSPCs. Deciphering the molecular determinants that underlie the observed importance of regionally matched grafts requires further study. Specifying NSPC fate toward precise regions of the spinal cord will be a key next step towards precision cell therapies for SCI.</p>","PeriodicalId":21986,"journal":{"name":"Stem Cells Translational Medicine","volume":"15 11","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13726807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149324720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michael H Carstens, Arlen Beatriz Ríos, Juan Sevilla, Carlos Rivera, Osman Pravia, Dorian Calero, Samuel Vilchez, Kenneth A Bertram, Anthony Atala
{"title":"Treatment of diabetic foot chronic ulcers and neuropathy with placenta-derived stem cells.","authors":"Michael H Carstens, Arlen Beatriz Ríos, Juan Sevilla, Carlos Rivera, Osman Pravia, Dorian Calero, Samuel Vilchez, Kenneth A Bertram, Anthony Atala","doi":"10.1093/stcltm/szag085","DOIUrl":"10.1093/stcltm/szag085","url":null,"abstract":"<p><strong>Aim: </strong>This first in human study sought to determine the safety and clinical effects of placenta-derived stem cells (PSCs) administered by injection in a dose-escalation trial in diabetic subjects with foot ulceration (DFU) and peripheral neuropathy (DPN).</p><p><strong>Methods: </strong>Subjects were enrolled with non-healing wounds of 10-100 cm2 despite standard therapy for ≥3 months. Objectives included safety, wound healing, changes in neuropathy and in ankle/foot vascular flow. Ten patients received PSC implantation to the DFU circumference, into the ulcer bed and along the pedal arteries, with a total dose escalation of 30, 40, and 60 million (M) cells in 4, 3, and 3 subjects, respectively.</p><p><strong>Results: </strong>There were no PSC-treatment related serious adverse events. Wound healing was demonstrated in 10/10 subjects at 6 months. DPN improved in all subjects; with 9 of 10 achieving normal protective sensation by 12 months.</p><p><strong>Conclusions: </strong>Local implantation of PSCs for DFU and DPN is safe and of potential clinical value.</p>","PeriodicalId":21986,"journal":{"name":"Stem Cells Translational Medicine","volume":"15 11","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13730048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149324722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mingyou Yu, Ziyi Zhang, Xuxian Wu, Baoying Zhang, Yang Hu, Changge Wei, Miao Ran, Manni Cao, Jinhui Zhang, Xueli Ding, Yan Wang, Can Liu, Maoqiong Chen, Jianwei Xu
{"title":"Human umbilical cord mesenchymal stem cells alleviate brain injury and promote neuroregeneration via BDNF/TrkB/CREB/PI3K-Akt pathway in preterm rats with intraventricular hemorrhage.","authors":"Mingyou Yu, Ziyi Zhang, Xuxian Wu, Baoying Zhang, Yang Hu, Changge Wei, Miao Ran, Manni Cao, Jinhui Zhang, Xueli Ding, Yan Wang, Can Liu, Maoqiong Chen, Jianwei Xu","doi":"10.1093/stcltm/szag086","DOIUrl":"10.1093/stcltm/szag086","url":null,"abstract":"<p><strong>Objective: </strong>To explore the neuroprotective effect and molecular mechanism of human umbilical cord mesenchymal stem cells (hUC-MSCs) in preterm rats with intraventricular hemorrhage (IVH), and provide experimental basis for clinical treatment of neonatal IVH.</p><p><strong>Methods: </strong>Tissue block adherence method was used to isolate and culture hUC-MSCs, and P4 Sprague-Dawley premature rats were divided into sham, IVH model, and hUC-MSC treatment groups. Collagenase VIIS was injected to establish IVH model, and hUC-MSCs were injected into lateral ventricles. Cell colonization, body weight, neurobehavior, brain histology, apoptosis, and related molecular indicators were detected via fluorescence tracking, behavioral tests, staining, RT-PCR, Western blot (WB), and ELISA. Bioinformatics combined with ANA12 blocking assay verified core pathways.</p><p><strong>Results: </strong>hUC-MSCs survived in rat brain for at least 7 days. Compared with the model group, the treatment group gained weight faster, neurobehavioral function was markedly improved, neuronal apoptosis decreased sharply, and brain tissue damage was alleviated. hUC-MSCs up-regulated anti-apoptotic, anti-inflammatory, antioxidant and neurogenesis-related molecules and activated BDNF/TrkB/CREB/PI3K-Akt pathway; TrkB blockade reversed all protective effects.</p><p><strong>Conclusion: </strong>hUC-MSCs exert multi-target neuroprotection by activating BDNF/TrkB/CREB/PI3K-Akt pathway, which offers a novel strategy for IVH treatment in preterm infants.</p>","PeriodicalId":21986,"journal":{"name":"Stem Cells Translational Medicine","volume":"15 11","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13675110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149207408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Min Kyung Park, Yun Bin Lee, Se-Mi Jung, Yoo-Wook Kwon, Jung-Hwan Yoon
{"title":"Human embryonic stem cell-derived mesenchymal stem cells ameliorate mitochondrial oxidative dysfunction in metabolic dysfunction-associated steatotic liver disease.","authors":"Min Kyung Park, Yun Bin Lee, Se-Mi Jung, Yoo-Wook Kwon, Jung-Hwan Yoon","doi":"10.1093/stcltm/szag089","DOIUrl":"10.1093/stcltm/szag089","url":null,"abstract":"<p><strong>Introduction: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common chronic liver disease with significant clinical burden. This study investigated the therapeutic potential of embryonic stem cell-derived mesenchymal stem cells (ESC-MSCs) in cellular and murine models of MASLD.</p><p><strong>Methods: </strong>HepG2 cells were treated with palmitic acid (PA) and then co-cultured with ESC-MSCs. C57BL/6 mice were fed a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) or a standard diet for 24 weeks. Either ESC-MSCs or vehicles were administered via tail vein injection at week 20. Lipid accumulation was assessed using Oil red O staining. Mitochondrial status was assessed using MitoTracker Red fluorescence, mtDNA content, reactive oxygen species (ROS), and antioxidant parameters.</p><p><strong>Results: </strong>ESC-MSC co-culture reduced PA-induced lipid accumulation, restored mitochondrial activity, decreased ROS, and increased superoxide dismutase (SOD) activity and glutathione redox balance. Expression of phosphorylated AMPK (p-AMPK), PGC1α, and PPARα was significantly upregulated. In CDAHFD-fed mice, ESC-MSC transplantation attenuated hepatic steatosis, restored mitochondrial DNA content, and reduced ROS accumulation with increased SOD activity and glutathione ratio. Hepatic expression of p-AMPK, PGC1α, and PPARα was also enhanced. These effects were abrogated by Compound C, an AMPK inhibitor. ESC-MSCs secreted hepatocyte growth factor (HGF), which activated AMPK, suggesting an HGF-AMPK axis may serve as a potential paracrine mechanism.</p><p><strong>Conclusion: </strong>ESC-MSCs ameliorated hepatic steatosis in MASLD models by restoring mitochondrial activity and reducing oxidative stress, possibly involving HGF-associated AMPK pathway modulation. These findings support the potential of ESC-MSC therapy for MASLD.</p>","PeriodicalId":21986,"journal":{"name":"Stem Cells Translational Medicine","volume":"15 11","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149300306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rachael Mooney, Eslam E Abd El-Fattah, Gary Ngai, Jacqueline Lara, Mohamed Hammad, Karen S Aboody
{"title":"Cell-based therapies for malignant glioma.","authors":"Rachael Mooney, Eslam E Abd El-Fattah, Gary Ngai, Jacqueline Lara, Mohamed Hammad, Karen S Aboody","doi":"10.1093/stcltm/szag084","DOIUrl":"10.1093/stcltm/szag084","url":null,"abstract":"<p><p>Despite innovative progress, cellular therapies have not produced durable, population-level survival gains in glioblastoma. Across 3 major modalities, engineered effectors such as chimeric antigen receptor T cell (CAR-T) and natural killer (NK) cells, immune-education platforms such as dendritic and whole-cell vaccines, and carrier cells delivering oncolytic or drug payloads, trials have shown measurable bioactivity, but durability has varied. This likely reflects systemic barriers, including therapy-induced lymphopenia, myeloid dominance, and T-cell sequestration, as well as local barriers such as antigen heterogeneity and immune suppression. To understand why some studies nevertheless showed more favorable efficacy signals, we reviewed clinical outcomes across these modalities and identified 4 recurring design features that appeared repeatedly among studies reporting more favorable survival signals: treatment in the minimal residual disease setting, a T-helper type 1 supportive context, broadened antigenic coverage, and effective immune hand-off from the initiating therapy to endogenous or adoptively transferred effectors. Across heterogeneous early-phase studies, greater feature alignment sometimes co-occurred with more favorable signals, although this retrospective pattern is descriptive and does not establish association or causality. These observations may help guide future biomarker-informed strategies and provide a practical framework for organizing multimodal trials aimed at converting transient bioactivity into more durable, polyclonal control.</p>","PeriodicalId":21986,"journal":{"name":"Stem Cells Translational Medicine","volume":"15 11","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13686766/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149239534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brianna M Doratt, Hami Hemati, Sheridan B Wagner, Madison B Blanton, Uriel Avila, Oleg Varlamov, Ilhem Messaoudi
{"title":"Maternal obesity primes fetal hematopoietic stem and progenitor cells toward myeloid differentiation in a nonhuman primate model.","authors":"Brianna M Doratt, Hami Hemati, Sheridan B Wagner, Madison B Blanton, Uriel Avila, Oleg Varlamov, Ilhem Messaoudi","doi":"10.1093/stcltm/szag091","DOIUrl":"10.1093/stcltm/szag091","url":null,"abstract":"<p><strong>Aim: </strong>Maternal obesity is a major global health challenge with profound consequences for offspring health. While its impact on metabolic programming has been widely studied, far less is known about how maternal factors influence fetal hematopoiesis and immune ontogeny. In this study, we examined fetal bone marrow (FBM) hematopoiesis in a nonhuman primate model of spontaneous maternal obesity maintained on a standard chow diet.</p><p><strong>Methods: </strong>In the present study, 6 lean (2 female, 4 male offspring) and 7 spontaneously obese (4 female, 3 male offspring) 8- to 12-year-old female rhesus macaques fed regular chow underwent time-mated breeding. FBM cells were assessed using spectral flow cytometry, single-cell transcriptional profiling, response to stimulation, in vitro differentiation and mitochondrial membrane potential.</p><p><strong>Results: </strong>Spectral flow cytometry demonstrated that maternal obesity altered abundance and composition of hematopoietic stem and progenitor cells (HSPCs), committed progenitors, and mature immune cell populations. Single-cell transcriptional profiling followed by pseudotime analysis revealed enrichment of early progenitor states with reduced representation of later differentiation states, accompanied by inflammatory transcriptional reprogramming characterized by increased expression of alarmins and interferon‑stimulated genes, particularly within myeloid progenitors. Cell-cell communication analyses predicted altered inflammatory signaling within hematopoietic niche. Functionally, HSPCs from the obese group exhibited enhanced priming for myeloid differentiation under in vitro differentiation conditions. Myeloid progenitors also displayed increased mitochondrial membrane potential, consistent with transcriptional metabolic reprogramming, whereas in vitro-differentiated monocytes exhibited altered lipopolysaccharide (LPS) induced cytokine response, characterized by reduced production of multiple analytes but increased tumor necrosis factor (TNF) production.</p><p><strong>Conclusions: </strong>Together, these results indicate that maternal obesity, even in absence of an obesogenic diet, is associated with remodeling of fetal hematopoietic development by altering HSPC composition, enriching immature differentiation-competent progenitor states, enhancing myeloid differentiation potential under myeloid-promoting conditions, and inducing transcriptional and functional changes in inflammatory responses. These findings provide new insight into how maternal obesity programs fetal hematopoiesis and may contribute to long-term alterations in offspring immune function.</p>","PeriodicalId":21986,"journal":{"name":"Stem Cells Translational Medicine","volume":"15 11","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13768128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149410905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Stem cell therapies for chronic obstructive pulmonary disease: mapping the global clinical trial landscape.","authors":"Tingting Xu, Wei Dai, Ziteng Zhu, Yuanrong Dai, Chan Chen, Xiangting Ge","doi":"10.1093/stcltm/szag087","DOIUrl":"10.1093/stcltm/szag087","url":null,"abstract":"<p><strong>Background: </strong>Stem cell therapies have emerged as a promising strategy for repairing structural damage and modulating inflammation in chronic obstructive pulmonary disease (COPD). However, a comprehensive characterization of the global clinical trial landscape remains lacking.</p><p><strong>Methods: </strong>We retrospectively analyzed clinical trials of stem cell therapy for COPD registered in the Trialtrove database up to October 1, 2025, supplemented by cross-referencing with ClinicalTrials.gov. Key trial characteristics were independently extracted and cross-checked by 2 investigators.</p><p><strong>Results: </strong>A total of 43 eligible trials were identified. Early-phase studies (Phase I-II) accounted for over 80% of all trials. Mesenchymal stromal cell (MSC)-based therapies and mixed cell populations each accounted for 34.9% of registered trials, followed by bronchial basal progenitor cell-based therapies (23.3%). Among 25 completed trials, only 11 publicly disclosed results. Available findings indicated no major short-term safety concerns for the specific cell products evaluated, whereas efficacy outcomes remained heterogeneous. Academic institutions sponsored most trials, while industry-sponsored studies showed a higher proportion of terminated or inactive trials. The United States and China accounted for the largest numbers of registered trials, although Brazil contributed the greatest number of publicly available outcome reports.</p><p><strong>Conclusions: </strong>Stem cell therapy for COPD remains in an early exploratory stage, with low result-disclosure rates and limited late-phase evidence. Standardized trial design, improved data transparency, and large-scale randomized controlled trials are urgently needed to advance clinical translation.</p>","PeriodicalId":21986,"journal":{"name":"Stem Cells Translational Medicine","volume":"15 11","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13726808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149324721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mahin Nikougoftar Zarif, Katia Lefsihane, Neda Khanlarkhani, Lina Sorvik, Jan Fredrik Talts, Katarina Le Blanc, Nadir Kadri
{"title":"HLA-DR modulation and PD-1/PD-L2 checkpoint signaling identify a mechanistic potency axis for mesenchymal stromal cell immunosuppression.","authors":"Mahin Nikougoftar Zarif, Katia Lefsihane, Neda Khanlarkhani, Lina Sorvik, Jan Fredrik Talts, Katarina Le Blanc, Nadir Kadri","doi":"10.1093/stcltm/szag090","DOIUrl":"10.1093/stcltm/szag090","url":null,"abstract":"<p><strong>Introduction: </strong>Mesenchymal stromal cells exhibit potent immunomodulatory properties and are under active investigation for the treatment of immune-mediated disorders. However, their clinical translation is hindered by the lack of standardized potency assays.</p><p><strong>Methods: </strong>Here, we established a reproducible mixed lymphocyte reaction platform by systematically optimizing peripheral blood mononuclear cell donor composition, culture conditions, and co-culture ratios to define a robust activation window.Using this optimized mixed lymphocyte reaction-based potency assay, we compared bone marrow and adipose-derived mesenchymal stromal cells across independent donor batches.</p><p><strong>Results: </strong>Both sources of mesenchymal stromal cells effectively suppressed T-cell proliferation, with the adipose-derived source demonstrating greater inhibitory activity under the experimental conditions, while a conserved lower threshold of suppression was observed across both sources. Mesenchymal stromal cells reduced early (CD25+) and late (CD25+ HLA-DR+) T-cell activation, with downregulation of CD25 and HLA-DR emerging as sensitive correlates of functional potency. Notably, bone marrow-derived mesenchymal stromal cells exerted stronger suppression of late-stage HLA-DR+ activation and preferentially inhibited CD8+ T-cell expansion, demonstrating source-dependent immunomodulatory functions. Mechanistically, this suppression was associated with modulation of the PD-1 pathway, characterized by decreased soluble PD-1, increased soluble PD-L1, and induction of soluble PD-L2 by mesenchymal stromal cells. PD-L2 levels inversely correlated with T-cell proliferation in the mixed lymphocyte reaction, supporting a PD-1/PD-L2 regulatory axis linked to mesenchymal stromal cell potency.</p><p><strong>Conclusion: </strong>These findings support a standardized and mechanistically informed mixed lymphocyte reaction-based potency assay framework integrating functional suppression, HLA-DR modulation, and PD-1/PD-L2 pathway signaling as complementary indicators of mesenchymal stromal cell activity.</p>","PeriodicalId":21986,"journal":{"name":"Stem Cells Translational Medicine","volume":"15 11","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13738804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149343533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marina de Cos, Samuel Mon-Wei Yu, Jacob Wright, Nanditha Anandakrishnan, Kristin Meliambro, Jenny S Wong, Evren Azeloglu, Kirk N Campbell
{"title":"Kidney organoids as a platform to study plasminogen-induced injury and uPA-based therapies.","authors":"Marina de Cos, Samuel Mon-Wei Yu, Jacob Wright, Nanditha Anandakrishnan, Kristin Meliambro, Jenny S Wong, Evren Azeloglu, Kirk N Campbell","doi":"10.1093/stcltm/szag078","DOIUrl":"10.1093/stcltm/szag078","url":null,"abstract":"<p><p>Urinary plasminogen has been implicated in the progression of proteinuric kidney diseases, yet its direct role in mediating injury along the nephron remains incompletely understood. Experimental models commonly used to study plasminogen-mediated damage are limited by incomplete phenotypic fidelity or interspecies differences, hindering translational relevance. Here, we used kidney organoids generated from H9 human embryonic stem cells to investigate the effects of plasminogen exposure and to evaluate urokinase-type plasminogen activator (uPA) inhibition with amiloride as a therapeutic strategy. Kidney organoids were exposed to plasminogen in the presence or absence of amiloride, and uPA activity was quantified using a fluorescence-based assay. Compartment-specific injury was assessed by confocal microscopy, automated image analysis, and AI-assisted nuclear segmentation, while targeted transcriptomic changes were evaluated using bulk quantitative PCR. Plasminogen exposure induced glomerular injury, characterized by reduced podocalyxin, nephrin, podocin, and WT1 expression, decreased glomerular cell density, and increased apoptosis. Proximal tubules exhibited reduced LTL and megalin expression, with increased KIM-1, whereas distal tubules were relatively preserved. Amiloride effectively inhibited uPA activity and partially restored podocyte and proximal tubular marker expression, but did not prevent apoptosis, indicating incomplete protection against plasminogen-induced injury. These findings support preferential plasminogen-induced injury along the glomerular-proximal tubular axis and highlight the utility of human kidney organoids for modeling this process, while underscoring the need for further validation and broader molecular profiling to strengthen their application in mechanistic studies and therapeutic discovery.</p>","PeriodicalId":21986,"journal":{"name":"Stem Cells Translational Medicine","volume":"15 10","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13593615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149017352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Single-cell transcriptomics reveals critical role of CD74 in bone marrow-derived mesenchymal stem cells.","authors":"Qinqin Xu, Carson Curtis, Jiahao Zhang, Arjun Verma, Aaron J Sheppard, Jeffrey Deng, Hicham Drissi, Shane Barton, Patrick Massey, Yufeng Dong","doi":"10.1093/stcltm/szag082","DOIUrl":"10.1093/stcltm/szag082","url":null,"abstract":"<p><strong>Background: </strong>Human bone marrow aspirates have been widely used for skeletal tissue regeneration. However, clinical outcomes of the tissue repair after transplantation are variable.</p><p><strong>Methods: </strong>In this study, we analyzed the molecular signatures and osteogenic differentiation potential of bone marrow-derived mesenchymal stromal cells (BMSCs) from different donors.</p><p><strong>Results: </strong>Our results clearly showed that BMSCs isolated from different patients exhibited different osteogenic capacities and growth rates. Moreover, single-cell RNA sequencing revealed that these BMSCs expressed elevated levels of genes associated with early osteogenesis, chondrogenesis, and adipogenesis. Differentially expressed genes related to cell cycles were enriched in clusters from all 5 different samples, suggesting these genes play an important role in BMSC maintenance and differentiation. More importantly, the BMSCs with the lowest osteogenic differentiation potential showed a dramatic decrease in the expression of cell surface protein CD74 when compared to other osteogenic genes. Knockdown of CD74 in BMSCs with high osteogenic potential significantly reduced their osteogenic capacity.</p><p><strong>Conclusions: </strong>These findings suggest that CD74 is a novel predictive marker of outcomes following BMSC transplantation. Furthermore, CD74-high BMSCs may represent a subpopulation of bone marrow cells responsible for bone marrow aspirate-mediated tissue regeneration.</p>","PeriodicalId":21986,"journal":{"name":"Stem Cells Translational Medicine","volume":"15 10","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149002559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}